J&J (JNJ) stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and talc-related legal issues are hurting J&J, a lot of this stock price decline could be due to the broader drug/biotech sector decline in the past month. Lower-than-expected sales of Lilly (LLY) and Novo Nordisk’s (NVO) popular diabetes and obesity drugs in the third quarter, guidance cuts, pipeline setbacks ...

The Health Care sector is often known for its stability during periods of economic turmoil. That’s not the case today, given uncertainty regarding future policy thanks to speculation that Robert F. Kennedy, Jr. will be appointed head of the DepartmentFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passio ...

More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic malignancies RARITAN, N.J., Nov. 19, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from Dece ...

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24Comprehensive results are being prepared for presentation at upcoming medical congressesSPRING HOUSE, Pa., Nov. 18, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal ...

Johnson & Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conference Call Participants Rick Wise - Stifel Rick Wise Okay everybody, Rick Wise again here and it is my pleasure and truly my privilege to welcome J&J to the 2024 Stifel Healthcare Conference. To my left, Michael Bodner, Group President, Heart Recovery and Circulatory Restoration. In the audience, two friends from I ...

Johnson & Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conference Call Participants Rick Wise - Stifel Rick Wise Okay everybody, Rick Wise again here and it is my pleasure and truly my privilege to welcome J&J to the 2024 Stifel Healthcare Conference. To my left, Michael Bodner, Group President, Heart Recovery and Circulatory Restoration. In the audience, two friends from I ...

Johnson & Johnson (JNJ) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving the combination of its intravenously administered EGFR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitorLazcluze (lazertinib) for use in certain patients with non-small cell lung cancer (NSCLC).The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions ...

Johnson & Johnson (NYSE:JNJ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wildgust - VP, Global Medical Affairs Oncology Conference Call Participants Vamil Divan - Guggenheim Securities Edouard Mullarky - Guggenheim Securities Vamil Divan All right. I think we're ready to get started. Thanks, everyone, again, for joining us at the Guggenheim Inaugural Healthcare Innovation Conference this ...

Johnson & Johnson (NYSE:JNJ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wildgust - VP, Global Medical Affairs Oncology Conference Call Participants Vamil Divan - Guggenheim Securities Edouard Mullarky - Guggenheim Securities Vamil Divan All right. I think we're ready to get started. Thanks, everyone, again, for joining us at the Guggenheim Inaugural Healthcare Innovation Conference this ...

Readers who have been with me for a while may know how hard it is for me to sell stocks. That is based on the fact that I hold a relatively small number of individual companies. Currently, I holdAnalyst’s Disclosure: I/we have a beneficial long position in the shares of EXR, REXR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship w ...